All section Close
Credits: Jagran
Maharashtra-Based Pharma Firm Files Complaint Against Serum Institute Over 'Covishield' Trademark
Writer: Devyani Madaik
A media enthusiast, Devyani believes in learning on the job and there is nothing off limits when it comes to work. Writing is her passion and she is always ready for a debate as well.
Maharashtra, 6 Jan 2021 12:55 PM GMT
Editor : Shubhendu Deshmukh |
Shubhendu, the quint essential news junky, the man who loves science and politics in equal measure and offers the complete contrast to it by being a fan of urdu poetry as well.
Creatives : Abhishek M
" An engineer by profession, Abhishek is the creative producer of the team, graphic designing is his passion and travelling his get away. In more ways than one, he makes the content visually appealing."
A civil court in Pune issued a notice to SII, seeking to restrain the former from using the trademark or other similar names for its vaccine
A Maharashtra-based pharmaceutical company Cutis-Biotech has filed a suit against the Serum Institute of India (SII) on Monday, January 4, for allegedly using the trademark 'Covishield' for its upcoming COVID-19 vaccine.
The firm claims that it has been using the trademark for its products like antiseptics, sanitiser, disinfectant liquid, surface spray, and fruit and vegetable washing since May 2020.
The civil court on Tuesday, in Pune issued a notice to SII, seeking to restrain the former from using the trademark or other similar names for its vaccine, NDTV reported.
Cutis-Biotech had applied for registration of the name last year, on April 29, and has been using it since May 30. The suit sought an injunction against the Pune-based firm from using the name.
Cutis added that SII could use one of the many names they have filed trademark applications for, including "COVIDOROTECT, COVID-VAC, COVI-VAC, COVI-VAXX".
"The SII vaccine is yet to be launched in the market. Therefore, if the injunction is issued against the defendant restraining it from using the plaintiff's trademark (Covishield), no inconvenience is going to be caused to the vaccine maker. However, if the SII launches its product under the brand "Covishield", injury and damage would be caused to Cutis-Biotech," the suit read.
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
